Marshall Wace
SRNE

Marshall Wace’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Marshall Wace’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-293,934
Closed -$461K – 3661
2022
Q3 		$461K Buy
+293,934
New +$667K ﹤0.01% 2775
2022
Q2 		– Sell
-1,658,516
Closed -$3.86M – 4022
2022
Q1 		$3.86M Buy
+1,658,516
New +$5.17M 0.01% 1586
2015
Q2 		– Sell
-44,352
Closed -$513K – 1085
2015
Q1 		$513K Buy
+44,352
New +$513K 0.01% 664

Other funds holding SRNE

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BRF
B. Riley Financial Los Angeles, California $434M AUM 751.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $43.9B AUM 121.74% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Marshall Wace's SRNE Position: Q4 2022 in Review

Marshall Wace sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2022, closing a stake of 293,934 shares — an estimated $461K sold.

Marshall Wace first reported a position in SRNE in Q1 2015 and held it in 3 quarters. The position peaked at $3.86M in Q1 2022. 221 funds tracked by Wall St. Rank hold SRNE as of Q4 2022.

  • Marshall Wace reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • Marshall Wace sold 293,934 Sorrento Therapeutics, Inc. shares in Q4 2022, an estimated $461K.
  • Marshall Wace first reported a position in Sorrento Therapeutics, Inc. in Q1 2015 and held it in 3 quarters.
  • Marshall Wace's Sorrento Therapeutics, Inc. position peaked at $3.86M in Q1 2022.
  • 221 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2022.

Based on Marshall Wace's 13F filing for Q4 2022, filed 14 Feb 2023.